Drug intelligence / Profile preview

LioCyx-H

Development stage: Preclinical
Lead developer: Lion TCR
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

LioCyx-H is a preclinical-stage T cell receptor engineered T cell (TCR-T) therapy being developed by Lion TCR for the treatment of HIV infection. The therapy utilizes the company's proprietary TCR-T platform to engineer a patient's T cells to express specific T cell receptors that recognize HIV antigens presented on the surface of infected cells. By targeting these antigen-expressing cells, LioCyx-H aims to facilitate the immune-mediated clearance of the HIV reservoir, offering a potential functional cure or long-term viral control strategy. The program is currently in the preclinical phase of development.

Beyond the preview

Go deeper on LioCyx-H.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LioCyx-H.

Explore the full profile